John V. Heymach

67.1k total citations · 14 hit papers
635 papers, 25.2k citations indexed

About

John V. Heymach is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, John V. Heymach has authored 635 papers receiving a total of 25.2k indexed citations (citations by other indexed papers that have themselves been cited), including 394 papers in Oncology, 361 papers in Pulmonary and Respiratory Medicine and 202 papers in Molecular Biology. Recurrent topics in John V. Heymach's work include Lung Cancer Treatments and Mutations (282 papers), Cancer Immunotherapy and Biomarkers (130 papers) and Cancer Genomics and Diagnostics (108 papers). John V. Heymach is often cited by papers focused on Lung Cancer Treatments and Mutations (282 papers), Cancer Immunotherapy and Biomarkers (130 papers) and Cancer Genomics and Diagnostics (108 papers). John V. Heymach collaborates with scholars based in United States, China and Japan. John V. Heymach's co-authors include Roy S. Herbst, Scott M. Lippman, Ferdinandos Skoulidis, Lauren A. Byers, Jing Wang, Tina Cascone, Ignacio I. Wistuba, Monique B. Nilsson, Lixia Diao and Xiuning Le and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

John V. Heymach

603 papers receiving 24.9k citations

Hit Papers

Lung Cancer 2007 2026 2013 2019 2008 2019 2019 2019 2007 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lung Cancer
    2008 2.0k citations Roy S. Herbst, John V. Heymach et al. profile →
  2. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
    2019 718 citations Lauren A. Byers, John V. Heymach et al. profile →
  3. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
    2019 630 citations John V. Heymach et al. profile →
  4. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
    2019 616 citations Triparna Sen, B. Leticia Rodriguez et al. Cancer Discovery profile →
  5. PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
    2007 598 citations John V. Heymach et al. Cancer Research profile →
  6. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
    2020 353 citations Joe Y. Chang, Patricia M. de Groot et al. profile →
  7. Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
    2016 349 citations Lixia Diao, Edwin R. Parra et al. Clinical Cancer Research profile →
  8. Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
    2014 255 citations Chad Tang, Erminia Massarelli et al. profile →
  9. Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
    2022 254 citations Monique B. Nilsson, John V. Heymach et al. Clinical Cancer Research profile →
  10. Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
    2020 228 citations Monique B. Nilsson, Martin Reck et al. profile →
  11. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer
    2018 214 citations Zhongxing Liao, J. Jack Lee et al. Journal of Clinical Oncology profile →
  12. Non-small-cell lung cancer
    2024 127 citations John V. Heymach, Martin Reck et al. profile →
  13. AI in drug discovery and its clinical relevance
    2023 125 citations John V. Heymach et al. profile →
  14. Antibody-drug conjugates in lung cancer: dawn of a new era?
    2023 80 citations John V. Heymach et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John V. Heymach United States 79 13.6k 11.1k 10.2k 5.4k 2.8k 635 25.2k
Giampaolo Tortora Italy 69 13.8k 1.0× 9.9k 0.9× 7.8k 0.8× 4.8k 0.9× 1.9k 0.7× 639 24.4k
David S. Hong United States 77 10.4k 0.8× 9.5k 0.9× 6.3k 0.6× 5.8k 1.1× 2.5k 0.9× 817 23.2k
Kenneth J. O’Byrne Australia 72 12.7k 0.9× 8.4k 0.8× 10.5k 1.0× 5.0k 0.9× 2.2k 0.8× 598 23.7k
Suresh S. Ramalingam United States 74 15.5k 1.1× 8.8k 0.8× 14.5k 1.4× 4.2k 0.8× 2.6k 1.0× 593 25.5k
Ravi Salgia United States 90 10.6k 0.8× 12.5k 1.1× 8.4k 0.8× 3.7k 0.7× 3.0k 1.1× 626 27.5k
D. Ross Camidge United States 77 15.0k 1.1× 8.6k 0.8× 16.9k 1.7× 4.6k 0.8× 1.1k 0.4× 539 24.2k
Ming‐Sound Tsao Canada 98 15.3k 1.1× 16.5k 1.5× 13.8k 1.4× 8.3k 1.5× 2.9k 1.0× 653 37.2k
Jeffrey A. Engelman United States 91 16.0k 1.2× 21.3k 1.9× 13.8k 1.3× 6.2k 1.1× 2.0k 0.7× 187 36.0k
Lecia V. Sequist United States 73 19.5k 1.4× 10.3k 0.9× 18.3k 1.8× 7.6k 1.4× 1.5k 0.5× 368 30.9k
Kazuhiko Nakagawa Japan 80 22.1k 1.6× 9.9k 0.9× 20.8k 2.0× 4.4k 0.8× 1.5k 0.5× 815 32.3k

Countries citing papers authored by John V. Heymach

Since Specialization
Citations

This map shows the geographic impact of John V. Heymach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John V. Heymach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John V. Heymach more than expected).

Fields of papers citing papers by John V. Heymach

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John V. Heymach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John V. Heymach. The network helps show where John V. Heymach may publish in the future.

Co-authorship network of co-authors of John V. Heymach

This figure shows the co-authorship network connecting the top 25 collaborators of John V. Heymach. A scholar is included among the top collaborators of John V. Heymach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John V. Heymach. John V. Heymach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heymach, John V., David H. Harpole, Tetsuya Mitsudomi, et al.. (2023). Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. Cancer Research. 83(8_Supplement). CT005–CT005. 55 indexed citations
2.
Ramkumar, Kavya, C. Allison Stewart, Kasey R. Cargill, et al.. (2020). AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Molecular Cancer Research. 19(3). 485–497. 38 indexed citations
3.
Sitthideatphaiboon, Piyada, Ana Galan Cobo, Marcelo V. Negrão, et al.. (2020). STK11 /LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. Clinical Cancer Research. 27(6). 1720–1733. 57 indexed citations
4.
Sen, Triparna, B. Leticia Rodriguez, Limo Chen, et al.. (2019). Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discovery. 9(5). 646–661. 616 indexed citations breakdown →
5.
Yan, Xiang, Xiaoshan Zhang, Li Wang, et al.. (2018). Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. Cancer Research. 79(1). 125–132. 62 indexed citations
6.
Gay, Carl M., Pan Tong, Robert J. Cardnell, et al.. (2018). Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. Clinical Cancer Research. 25(1). 346–357. 12 indexed citations
7.
Zhang, Jiexin, Li Shen, Xiayu Rao, et al.. (2017). CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Research. 78(3). 781–797. 34 indexed citations
8.
Tang, Chad, James W. Welsh, Patricia M. de Groot, et al.. (2016). Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clinical Cancer Research. 23(6). 1388–1396. 251 indexed citations
9.
Parra, Edwin R., Carmen Behrens, Jaime Rodriguez‐Canales, et al.. (2016). Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients. Clinical Cancer Research. 22(24). 6278–6289. 103 indexed citations
10.
Balaji, Kavitha, Smruthi Vijayaraghavan, Lixia Diao, et al.. (2016). AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research. 15(1). 45–58. 70 indexed citations
11.
Welsh, James W., Ritsuko Komaki, Arya Amini, et al.. (2013). Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 31(7). 895–902. 314 indexed citations
12.
Cardnell, Robert J., Ying Feng, Lixia Diao, et al.. (2013). Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer. Clinical Cancer Research. 19(22). 6322–6328. 131 indexed citations
13.
Rabellino, Andrea, Brandon Carter, Georgia Konstantinidou, et al.. (2012). The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA. Cancer Research. 72(9). 2275–2284. 94 indexed citations
14.
Sano, Daisuke, Fumihiko Matsumoto, David R. Valdecanas, et al.. (2011). Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation In Vivo and In Vitro. Clinical Cancer Research. 17(7). 1815–1827. 59 indexed citations
15.
Xie, Yang, Guanghua Xiao, Kevin R. Coombes, et al.. (2011). Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non–Small-Cell Lung Cancer Patients. Clinical Cancer Research. 17(17). 5705–5714. 130 indexed citations
16.
Yang, Fei, Ximing Tang, Erick Riquelme, et al.. (2011). Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. Cancer Research. 71(16). 5512–5521. 51 indexed citations
17.
Moeller, Benjamin J., John S. Yordy, Michelle D. Williams, et al.. (2011). DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy. Clinical Cancer Research. 17(7). 2035–2043. 75 indexed citations
18.
Cai, Di, David S. Shames, Maria Gabriela Raso, et al.. (2010). Steroid Receptor Coactivator-3 Expression in Lung Cancer and Its Role in the Regulation of Cancer Cell Survival and Proliferation. Cancer Research. 70(16). 6477–6485. 48 indexed citations
19.
Hanrahan, Emer O., Anderson J. Ryan, Helen Mann, et al.. (2009). Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer. Clinical Cancer Research. 15(10). 3600–3609. 69 indexed citations
20.
Kamat, Aparna A., Tae Jin Kim, Charles N. Landen, et al.. (2007). Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer. Cancer Research. 67(1). 281–288. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giampaolo Tortora Breakdown of academic impact, for papers by David S. Hong Breakdown of academic impact, for papers by Kenneth J. O’Byrne Breakdown of academic impact, for papers by Suresh S. Ramalingam Breakdown of academic impact, for papers by Ravi Salgia Breakdown of academic impact, for papers by D. Ross Camidge Breakdown of academic impact, for papers by Ming‐Sound Tsao Breakdown of academic impact, for papers by Jeffrey A. Engelman Breakdown of academic impact, for papers by Lecia V. Sequist Breakdown of academic impact, for papers by Kazuhiko Nakagawa
Rankless by CCL
2026